Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 02, 2023 | May 04, 2023 |
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director · Chairman, President & CEO | August 03, 2026 | August 05, 2026 |
| CVS HEALTH CorpCVS · Entity 2884 | Director | May 14, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 02, 2023 · Filed May 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 9,692 |
Reported balance
After 2023-05-02 transaction · row 1
1 source rowRow 1 · 2023-05-02 · Grant · Acquired 4,573 · Balance 9,692 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. |
| Common Stock, $1 par valueSEC Table I · non-derivative | IndirectShares owned by Michael F. Mahoney Revocable Trust | 20,397 |
Reported balance
Holding disclosure · report date 2023-05-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,397 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
BOSTON SCIENTIFIC CORP
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,590,024 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 186,240 · Balance 1,590,024 F1: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 22,119 |
Reported balance
After 2026-08-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-03 · Other · Acquired 22,119 · Balance 22,119 F2: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
CVS HEALTH Corp
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,428.8174 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 1,737.0046 · Balance 6,428.8174 F1: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. F2: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
F2: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | OtherCommon Stock | 22,119 | $48.43 | $1,071,223.17 |
DisclosureSEC source: 0001225208-26-006950 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By 401(k) Disclosed balance after: 22,119 F2 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | PurchaseCommon Stock | 186,240 | $48.33 | $9,001,407.55 |
DisclosureSEC source: 0001225208-26-006950 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,590,024 F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 386,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005670 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee. Read SEC document |
| May 14, 2026 Filed May 15, 2026 21:23 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantDeferred Stock Units · Derivative | 1,737.0046 | $97.15 Strike: $0.00 | $168,750.00 |
DisclosureSEC source: 0000064803-26-000078 · form4.xml · derivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,428.8174 Underlying: Common Stock · 1,737.0046 shares Expires not disclosed F1 · kind: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. F2 · derivative.exercise_date: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. F2 · derivative.expiration_date: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 12 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,265 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,865 | $74.73 | $587,751.45 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,860 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,584,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 11 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,524 Underlying: Common Stock · 16,524 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,990 | $74.73 | $597,092.70 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,568,460 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 8,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 10 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,498 Underlying: Common Stock · 8,832 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 132,099 | $74.73 | $9,871,758.27 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559,926 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 8,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,692,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 132,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683,193 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 132,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,551,003 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 131,329 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002016 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,329 Underlying: Common Stock · 131,329 shares Expires 2036-02-12 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 55,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002016 · doc4.xml · derivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,652 Underlying: Common Stock · 55,652 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 13,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002016 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,408 Underlying: Common Stock · 13,704 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,626 | $74.12 | $491,119.12 |
DisclosureSEC source: 0001225208-26-002016 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,418,813 Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002016 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,425,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,407 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,814 Underlying: Common Stock · 49,407 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,347 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,739 Underlying: Common Stock · 46,347 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 159,701 | $93.49 | $14,930,526.34 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,411,735 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.985, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,200 | $94.06 | $112,868.04 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,571,436 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 46,347 | $27.09 | $1,255,540.23 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,572,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 49,407 | $24.55 | $1,212,941.85 |
DisclosureSEC source: 0001225208-26-001156 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,526,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantDeferred Stock Units · Derivative | 2,021.9621 | $76.04 Strike: $0.00 | $153,750.00 |
DisclosureSEC source: 0000064803-25-000063 · form4.xml · derivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,613.3964 Underlying: Common Stock · 2,021.9621 shares Expires not disclosed F1 · shares: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. F2 · derivative.exercise_date: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. F2 · derivative.expiration_date: Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 149,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008843 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 213,679 F3 · kind: This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney Term Irrevocable Trust - 2025, which is administered by an independent trustee. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 73,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008843 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 363,671 F2 · kind: This transaction involved a gift of securities by The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2024, which is administered by an independent trustee. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 88,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008843 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 289,675 F1 · kind: This transaction involved a gift of securities by The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2023, which is administered by an independent trustee. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,407 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,221 Underlying: Common Stock · 49,407 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,212 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,212 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 89,921 | $103.39 | $9,296,950.17 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,476,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.83 to $103.825 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 74,522 | $104.05 | $7,754,185.50 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,566,803 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.83 to $104.755, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 49,407 | $24.55 | $1,212,941.85 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,641,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,212 | $17.26 | $970,219.12 |
DisclosureSEC source: 0001225208-25-005681 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,591,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:46 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantDeferred Stock Units · Derivative | 2,542.5831 | $60.47 Strike: $0.00 | $153,750.00 |
DisclosureSEC source: 0001127602-25-014956 · form4.xml · derivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,542.5831 Underlying: Common Stock · 2,542.5831 shares Expires not disclosed F2 · kind: Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. F3 · derivative.exercise_date: Consists of Deferred Stock Compensation payable pursuant to Insider's election F3 · derivative.expiration_date: Consists of Deferred Stock Compensation payable pursuant to Insider's election Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:46 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 144 | $60.47 | $8,707.68 |
DisclosureSEC source: 0001127602-25-014956 · form4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,345 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,407 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,628 Underlying: Common Stock · 49,407 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,212 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,212 Underlying: Common Stock · 56,212 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 91,282 | $102.13 | $9,322,265.53 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,535,706 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.61 to $102.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 73,161 | $102.92 | $7,529,708.17 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,626,988 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.64 to $103.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 49,407 | $24.55 | $1,212,941.85 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,700,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,212 | $17.26 | $970,219.12 |
DisclosureSEC source: 0001225208-25-004717 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,650,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,407 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-25-003866 · doc4.xml · derivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,035 Underlying: Common Stock · 49,407 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,211 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-25-003866 · doc4.xml · derivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,424 Underlying: Common Stock · 56,211 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 164,442 | $100.01 | $16,445,071.54 |
DisclosureSEC source: 0001225208-25-003866 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,594,530 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.50 to $100.40, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 49,407 | $24.55 | $1,212,941.85 |
DisclosureSEC source: 0001225208-25-003866 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,758,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 56,211 | $17.26 | $970,201.86 |
DisclosureSEC source: 0001225208-25-003866 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,709,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 17:35 UTC | CVS HEALTH Corp CVS · Entity 2884 | PurchaseCommon Stock (By Trust) | 30,000 | $66.70 | $2,001,000.00 |
DisclosureSEC source: 0001127602-25-005398 · form4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,356 F1 · security: Consists of shares held in trusts for the benefit of the reporting person or the reporting person and his spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.